A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Zhang, Shaojun ^a   Yuan, Yuan ^a   Hao, Dapeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PLATINUM COMPLEX; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DNA REPAIR; DRUG RESPONSE; DRUG SENSITIVITY; EMSY GENE; EPIGENETICS; FEMALE; GENE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SILENCING; GENOMIC INSTABILITY; GENOMIC INSTABILITY SCORE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SOMATIC MUTATION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; VERY ELDERLY; CHEMISTRY; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84919330206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113169     Document Type: Article

References (42)

1. D'Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3: 23-34.
2. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819.
3. Venkitaraman AR (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 4: 266-276.
4. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530-5536.
5. Helleday T, Lo J, van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6: 923-935.
6. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, et al. (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26: 20-25.
7. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, et al. (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20: 463-466.
8. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195.
9. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, et al. (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104: 1004-1012.
10. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999) Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 59: 868-871.
11. Johannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16: 397-404.
12. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
13. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
14. O'Driscoll M (2008) Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders. Curr Genomics 9: 137-146.
15. Kang J, D'Andrea AD, Kozono D (2012) A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 104: 670-681.
16. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
17. Kennedy RD, D'Andrea AD (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24: 3799-3808.
18. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009) Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17: 722-731.
19. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
20. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
21. Huertas P (2010) DNA resection in eukaryotes: deciding how to fix the break. Nat Struct Mol Biol 17: 11-16.
22. Park S, Yang JS, Shin YE, Park J, Jang SK, et al. (2011) Protein localization as a principal feature of the etiology and comorbidity of genetic diseases. Mol Syst Biol 7: 494.
23. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569.
24. Chiang JW, Karlan BY, Cass L, Baldwin RL (2006) BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 101: 403-410.
25. Stefansson OA, Villanueva A, Vidal A, Marti L, Esteller M (2012) BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7: 1225-1229.
26. Brown LA, Irving J, Parker R, Kim H, Press JZ, et al. (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100: 264-270.
27. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322.
28. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A (2008) A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7: 2010-2019.
29. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204.
30. Brandsma I, Gent DC (2012) Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr 3: 9.
31. Chapman JR, Taylor MR, Boulton SJ (2012) Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47: 497-510.
32. Shrivastav M, De Haro LP, Nickoloff JA (2008) Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147.
33. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, et al. (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2: 366-375.
34. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, et al. (2012) Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107: 1776-1782.
35. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, et al. (2012) Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72: 5454-5462.
36. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, et al. (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 11: R47.
37. Baumbusch LO, Helland A, Wang Y, Liestol K, Schaner ME, et al. (2013) High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 8: e54356.
38. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, et al. (2011) Chemotherapy in epithelial ovarian cancer. Cancer letters 303: 73-83.
39. Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, et al. (2011) Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 120: 224-228.
40. Herzog TJ (2003) Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol 90: S3-7.
41. Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348: 2339-2347.
42. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646.